Rautenstrauch H, Laschner W, Saal J G
Z Rheumatol. 1985 Jul-Aug;44(4):192-7.
In 52 patients with severe rheumatoid arthritis the therapeutic efficacy of 600 mg/die of D-penicillamine was evaluated for two years in a prospective trial. Patients were included in the study only if the duration of their disease exceeded 6 months (upper limit 12 months), and there was involvement of 6 or more joints and an elevated erythrocyte sedimentation rate (1 hour values greater than or equal to 25 mm). In 26 patients (50%) a decline in the activity index could be observed, but 18 of these subjects had a deterioration of findings as assessed by X-ray. The increase of the activity index indicated no therapeutic benefit in 26 patients (50%), which could be confirmed in 23 subjects by X-rays.
在一项前瞻性试验中，对52例重度类风湿性关节炎患者使用每日600毫克青霉胺进行了为期两年的治疗效果评估。仅当疾病持续时间超过6个月（上限为12个月）、有6个或更多关节受累且红细胞沉降率升高（1小时值大于或等于25毫米）时，患者才被纳入研究。26例患者（50%）的活动指数有所下降，但其中18例患者经X线评估病情出现恶化。26例患者（50%）的活动指数升高表明未获得治疗益处，这在23例患者的X线检查中得到证实。
